BR112023025003A2 - Métodos para tratar o câncer de mama - Google Patents

Métodos para tratar o câncer de mama

Info

Publication number
BR112023025003A2
BR112023025003A2 BR112023025003A BR112023025003A BR112023025003A2 BR 112023025003 A2 BR112023025003 A2 BR 112023025003A2 BR 112023025003 A BR112023025003 A BR 112023025003A BR 112023025003 A BR112023025003 A BR 112023025003A BR 112023025003 A2 BR112023025003 A2 BR 112023025003A2
Authority
BR
Brazil
Prior art keywords
breast cancer
methods
treating breast
individual
adjuvant
Prior art date
Application number
BR112023025003A
Other languages
English (en)
Portuguese (pt)
Inventor
Anitra Fielding
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023025003A2 publication Critical patent/BR112023025003A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR112023025003A 2021-06-02 2022-05-31 Métodos para tratar o câncer de mama BR112023025003A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02
PCT/EP2022/064697 WO2022253800A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Publications (1)

Publication Number Publication Date
BR112023025003A2 true BR112023025003A2 (pt) 2024-02-20

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025003A BR112023025003A2 (pt) 2021-06-02 2022-05-31 Métodos para tratar o câncer de mama

Country Status (12)

Country Link
US (1) US20240269135A1 (https=)
EP (1) EP4346828A1 (https=)
JP (1) JP2024520142A (https=)
KR (1) KR20240016344A (https=)
CN (1) CN118139624A (https=)
AU (1) AU2022286616A1 (https=)
BR (1) BR112023025003A2 (https=)
CA (1) CA3220751A1 (https=)
CL (1) CL2023003533A1 (https=)
IL (1) IL308684A (https=)
MX (1) MX2023014420A (https=)
WO (1) WO2022253800A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
JP2024520142A (ja) 2024-05-21
CA3220751A1 (en) 2022-12-08
MX2023014420A (es) 2024-04-23
CN118139624A (zh) 2024-06-04
WO2022253800A1 (en) 2022-12-08
US20240269135A1 (en) 2024-08-15
KR20240016344A (ko) 2024-02-06
AU2022286616A1 (en) 2024-01-18
IL308684A (en) 2024-01-01
EP4346828A1 (en) 2024-04-10
CL2023003533A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
MX2023013912A (es) Metodos para inhibir ras.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112022023254A2 (pt) Monoterapias e terapias de combinação
BR112023006364A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
CR20240296A (es) Inhibidores parp1
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112023003427A2 (pt) Terapia com antagonista de lag-3 para carcinoma hepatocelular
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer
MX2024007260A (es) Uso de terapia de combinacion para tratar el cancer.
MX2023002851A (es) Tratamiento de la enfermedad de parkinson.
CL2024001678A1 (es) Tratamiento del cáncer con un inhibidor de la cinasa fgfr
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
BR112023025003A2 (pt) Métodos para tratar o câncer de mama
CO2024001405A2 (es) Composiciones y métodos para el tratamiento de cáncer
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2022005350A (es) El uso de una formulacion liposomal cationica que comprende paclitaxel y uno o mas lipidos cationicos, y opcionalmente gemcitabina, para el tratamiento de cancer pancreatico refractario o resistente.
BR112019004906A2 (pt) combinação incluindo abx196 para o tratamento de câncer
MX2024005220A (es) Endoxifeno para el tratamiento del cancer.
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]